Table 1

Azithromycin for ocular toxoplasmosis

Patient No, sex, age (years)Indication for treatmentInterval between onset and azithromycine medication (weeks)Size of retinal lesion (DD)Duration of retinitis (weeks)ComplicationsAdditional treatmentVisual acuityFollow up (months)Retinitis recurrence (follow up, months)
1, M, 25patient’s choice<113increase of vitreous opacitiespyrimethamine and prednisone20/5020/2021
2, M, 44patient’s choice22.56increase of vitreous opacitiespyrimethamine and prednisone20/6020/2020+ (5)
3, F, 24patient’s choice<11420/3020/2522+ (6)
4, M, 43patient’s choice<138increase of vitreous opalcitiespyrimethamine and sulphadiazine20/6020/2020
5, F, 33patient’s choice<11320/3020/2020
6, M, 28intolerant to triple treatment 50.54prednisone20/20020/2521
7, F, 31progressive disease with triple treatment >867LPLP 20
8, F, 29progressive disease with triple treatment >843CF20/200 21
9, M, 54progressive disease with triple treatment 82420/6020/2523
10, F, 73intolerant to triple treatment 335HMHM 20+ (7)
11, F, 69intolerant to triple treatment 21.54CF20/5013
  • Triple treatment included pyrimethamine, sulphadiazine, prednisone, and leucovorin.

  • Subnormal visual acuity was caused by large macular lesion and optic nerve atrophy (patient 7), optic nerve atrophy (patient 8) and by retinal artery occlusion (patient 10).